NASDAQ:VVUS VIVUS Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.28 -0.09 (-24.32 %) (As of 09/16/2020 12:00 AM ET) Add Compare Share Today's Range$0.25Now: $0.28▼$0.3850-Day Range$0.07MA: $0.19▼$0.4752-Week Range$0.44Now: $0.28▼$4.75Volume1.63 million shsAverage Volume1.44 million shsMarket Capitalization$5.00 millionP/E RatioN/ADividend YieldN/ABeta-0.84 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, and nonalcoholic steatohepatitis; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; Alvogen Malta Operations (ROW) Ltd; and Janssen Pharmaceuticals, Inc. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingVIVUS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.75, VIVUS has a forecasted upside of 525.0% from its current price of $0.28.Amount of Analyst CoverageVIVUS has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesVIVUS has received 376 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVIVUS has received 439 “underperform” votes. (Add your “underperform” vote.)Community SentimentVIVUS has received 53.87% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote “Outperform” if you believe VVUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVIVUS does not currently pay a dividend.Dividend GrowthVIVUS does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VIVUS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.00% of the stock of VIVUS is held by insiders.Percentage Held by InstitutionsOnly 7.32% of the stock of VIVUS is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for VIVUS are expected to grow in the coming year, from ($1.85) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VIVUS is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VIVUS is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.19 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:VVUS Previous Symbol CUSIP92855110 CIK881524 Webwww.vivus.com Phone650-934-5200Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.28Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$69.76 million Price / Sales0.07 Cash FlowN/A Price / Cash FlowN/A Book Value($6.50) per share Price / Book-0.04Profitability EPS (Most Recent Fiscal Year)($2.96) Net Income$-31,500,000.00 Net Margins-39.28% Return on EquityN/A Return on Assets-12.18%Miscellaneous Employees57 Outstanding Shares17,867,000Market Cap$5.00 million Next Earnings DateN/A OptionableOptionable $0.28 -0.09 (-24.32 %) (As of 09/16/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VVUS News and Ratings via Email Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter. VIVUS (NASDAQ:VVUS) Frequently Asked Questions How has VIVUS's stock been impacted by COVID-19 (Coronavirus)? VIVUS's stock was trading at $1.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VVUS shares have decreased by 73.1% and is now trading at $0.28. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of VIVUS? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VIVUS in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for VIVUS. How were VIVUS's earnings last quarter? VIVUS, Inc. (NASDAQ:VVUS) announced its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.31. The biopharmaceutical company earned $19.63 million during the quarter. View VIVUS's earnings history. When did VIVUS's stock split? How did VIVUS's stock split work? Shares of VIVUS reverse split on Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for VVUS? 1 brokers have issued 12 month target prices for VIVUS's stock. Their forecasts range from $1.75 to $1.75. On average, they expect VIVUS's share price to reach $1.75 in the next year. This suggests a possible upside of 525.0% from the stock's current price. View analysts' price targets for VIVUS. Who are some of VIVUS's key competitors? Some companies that are related to VIVUS include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Royalty Pharma (RPRX), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of VIVUS own? Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Novavax (NVAX), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Amarin (AMRN), Geron (GERN) and Idera Pharmaceuticals (IDRA). Who are VIVUS's key executives? VIVUS's management team includes the following people: Mr. John P. Amos, CEO & Director (Age 52)Mr. Kenneth Suh, Pres (Age 43)Mr. Mark K. Oki, Sr. VP, CFO & Chief Accounting Officer (Age 50)Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 54)Dr. Santosh T. Varghese, Chief Medical Officer (Age 49) What is VIVUS's stock symbol? VIVUS trades on the NASDAQ under the ticker symbol "VVUS." How do I buy shares of VIVUS? Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is VIVUS's stock price today? One share of VVUS stock can currently be purchased for approximately $0.28. How big of a company is VIVUS? VIVUS has a market capitalization of $5.00 million and generates $69.76 million in revenue each year. The biopharmaceutical company earns $-31,500,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. VIVUS employs 57 workers across the globe. What is VIVUS's official website? The official website for VIVUS is www.vivus.com. How can I contact VIVUS? VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
